AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29309313 — intervention group
Group type: COMPARATOR
Intervention: AMPS SHAM (placebo) applied twice a week for 4 weeks delivering subliminal stimulus.
Number of subjects: 30
Study 26343552 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) with adjunctive use of an essential-oil (EO)-based oral rinse for 30 days
Number of subjects: 60
Study 26343552 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone with water rinse for 30 days
Number of subjects: 60
Study 26247702 — intervention group
Group type: EXPERIMENTAL
Intervention: Same gender companion
Number of subjects: 216
Study 26247702 — intervention group
Group type: COMPARATOR
Intervention: Opposite gender companion
Number of subjects: 216
Study 22961571 — intervention group
Group type: EXPERIMENTAL
Intervention: More Intensive (MI) regimen
Number of subjects: 1606
Study 22961571 — intervention group
Group type: EXPERIMENTAL
Intervention: No Change (NC) regimen
Number of subjects: 1606
Study 22961571 — intervention group
Group type: COMPARATOR
Intervention: Less Intensive (LI) regimen
Number of subjects: 1606
Study 20830647 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief emotion-focused psychotherapy
Number of subjects: 34
Study 20830647 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred psychotherapy
Number of subjects: 34
Study 18458209 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention modeled on the Baby‐Friendly Hospital Initiative by WHO and UNICEF
Number of subjects: 17046
Study 18458209 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17046
Study 16740868 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy interventions
Number of subjects: 15
Study 12700501 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 0
Study 12700501 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification
Number of subjects: 0
Study 12700501 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy for diagnosis
Number of subjects: 0
Study 11194383 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane and remifentanil
Number of subjects: 62
Study 11194383 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane and remifentanil
Number of subjects: 62
Study 9369828 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefotetan (2 gm intravenous)
Number of subjects: 109
Study 9369828 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose cefotetan (2 gm intravenous every 12 hours for a minimum of 48 hours)
Number of subjects: 109
Study 9369828 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefotetan
Number of subjects: 109
Study 9369828 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose cefotetan
Number of subjects: 109
Study 31855086 — intervention group
Group type: EXPERIMENTAL
Intervention: HL301 (600 mg/day)
Number of subjects: 246
Study 31855086 — intervention group
Group type: COMPARATOR
Intervention: Umckamin (333 mg/day)
Number of subjects: 246
Study 31720257 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (13.5 g Hi-Maize 260 daily for 4 weeks)
Number of subjects: 21
Study 31720257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 28409364 — intervention group
Group type: COMPARATOR
Intervention: CL + D
Number of subjects: 32
Study 28409364 — intervention group
Group type: EXPERIMENTAL
Intervention: RL and RL + D
Number of subjects: 32
Study 26271080 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental monitoring
Number of subjects: 3349
Study 26271080 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-adolescent communication
Number of subjects: 3349
Study 26271080 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-adolescent communication (mediator)
Number of subjects: 3349
Study 23739960 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flash suppression (CFS)
Number of subjects: 0
Study 23739960 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher contrast targets
Number of subjects: 0
Study 23739960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest contrast target rendered invisible by CFS
Number of subjects: 0
Study 21411598 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-rEPA
Number of subjects: 301
Study 21411598 — intervention group
Group type: COMPARATOR
Intervention: Control (EPI vaccines alone)
Number of subjects: 301
Study 21411598 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-rEPA and Hib-TT
Number of subjects: 301
Study 18651193 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga use for health
Number of subjects: 31044
Study 15988081 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment with Depakin (30 mg/kg) and Mexidol (5 mg/kg) in children with generalized epilepsy.
Number of subjects: 220
Study 15988081 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with Mexidol (5 mg/kg) in children with first episode of febrile seizures.
Number of subjects: 220
Study 15988081 — intervention group
Group type: COMPARATOR
Intervention: Control group treated only with Depakin in children with generalized epilepsy.
Number of subjects: 220
Study 15988081 — intervention group
Group type: COMPARATOR
Intervention: Control group without any treatment in children with first episode of febrile seizures.
Number of subjects: 220
Study 12184060 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 58
Study 12184060 — intervention group
Group type: COMPARATOR
Intervention: Eprosartan (600 mg/day)
Number of subjects: 58
Study 10491894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dipyridamole 10 mg every 8 hours
Number of subjects: 60
Study 10491894 — intervention group
Group type: COMPARATOR
Intervention: Oral aspirin 300 mg every 24 hours
Number of subjects: 60
Study 8708728 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (DaunoXome) 40 mg/m2
Number of subjects: 232
Study 8708728 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin, bleomycin, and vincristine (ABV) regimen
Number of subjects: 232
Study 8708728 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (DaunoXome)
Number of subjects: 232
Study 1768819 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 16
Study 1768819 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 16
Study 6753911 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 37.5 mg, 75 mg or 150 mg/day for 7 weeks
Number of subjects: 475
Study 6753911 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus placebo
Number of subjects: 475
Study 6753911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study 6753911 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus hydrochlorothiazide 25 mg twice daily
Number of subjects: 475
Study 6753911 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 475
Study 6753911 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 475
Study 30877851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with D-cycloserine augmentation
Number of subjects: 136
Study 30877851 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) with placebo augmentation
Number of subjects: 136
Study 28712074 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg/day SHP465 MAS
Number of subjects: 275
Study 28712074 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 mg/day SHP465 MAS
Number of subjects: 275
Study 28712074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 26825824 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low-dose oral cyclophosphamide 50 mg and methotrexate 2.5 mg (maintenance arm)
Number of subjects: 60
Study 26825824 — intervention group
Group type: COMPARATOR
Intervention: Observation arm (control)
Number of subjects: 60
Study 24956453 — intervention group
Group type: EXPERIMENTAL
Intervention: GA with a single‐injection TPVB and placebo paravertebral infusion
Number of subjects: 180
Study 24956453 — intervention group
Group type: EXPERIMENTAL
Intervention: GA with a continuous TPVB
Number of subjects: 180
Study 24956453 — intervention group
Group type: COMPARATOR
Intervention: Standardized GA
Number of subjects: 180
Study 22103956 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-week group intervention including parenting, adolescent coping, and conjoint family sessions
Number of subjects: 516
Study 22103956 — intervention group
Group type: COMPARATOR
Intervention: Low-dosage control group workshop
Number of subjects: 516
Study 19924281 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(B)
Number of subjects: 191
Study 19924281 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02(A)
Number of subjects: 191
Study 19924281 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS vaccines (pooled)
Number of subjects: 191
Study 19924281 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine (control)
Number of subjects: 191
Study 17207676 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal brace technique
Number of subjects: 8
Study 17207676 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis activation during brace
Number of subjects: 8
Study 17207676 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hollowing technique
Number of subjects: 8
Study 15211082 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 124
Study 15211082 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 124
Study 15211082 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin and Vancomycin
Number of subjects: 124
Study 11581040 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia without intravenous sedatives
Number of subjects: 19250
Study 11581040 — intervention group
Group type: COMPARATOR
Intervention: Injection anesthesia without intravenous sedatives
Number of subjects: 19250
Study 11581040 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia with intravenous sedatives
Number of subjects: 19250
Study 11581040 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection anesthesia with intravenous sedatives
Number of subjects: 19250
Study 11581040 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection anesthesia with short-acting hypnotic agents (alone)
Number of subjects: 19250
Study 11581040 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection anesthesia with short-acting hypnotic agents (with opiates)
Number of subjects: 19250
Study 11581040 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection anesthesia with short-acting hypnotic agents (with sedatives)
Number of subjects: 19250
Study 11581040 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection anesthesia with short-acting hypnotic agents (with opiates and sedatives)
Number of subjects: 19250
Study 9636865 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution (100 mg once daily for 14 days)
Number of subjects: 244
Study 9636865 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole capsules (100 mg once daily for 14 days)
Number of subjects: 244
Study 9636865 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution (100 mg twice daily for 7 days)
Number of subjects: 244
Study 8179396 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideco autotransfusion system
Number of subjects: 28
Study 8179396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorin autotransfusion system
Number of subjects: 28
Study 8179396 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 3276670 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine in combination with methadone
Number of subjects: 0
Study 3276670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30446894 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5*1/*1 genotype
Number of subjects: 0
Study 30446894 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5*1/*3 genotype
Number of subjects: 0
Study 30446894 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5*3/*3 genotype
Number of subjects: 0
Study 30446894 — intervention group
Group type: COMPARATOR
Intervention: CYP3A5*1/*1 vs CYP3A5*1/*3
Number of subjects: 0
Study 30446894 — intervention group
Group type: COMPARATOR
Intervention: CYP3A5*1/*1 vs CYP3A5*3/*3
Number of subjects: 0
Study 30446894 — intervention group
Group type: COMPARATOR
Intervention: Delayed graft functioning
Number of subjects: 0
Study 28566364 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet preservation
Number of subjects: 88
Study 28566364 — intervention group
Group type: COMPARATOR
Intervention: Leaflet resection
Number of subjects: 88
Study 25661282 — intervention group
Group type: EXPERIMENTAL
Intervention: suvorexant (40 mg in <65 y-olds; 30 mg in ≥65 y-olds)
Number of subjects: 25
Study 25661282 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 23426612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask Positive Pressure Ventilation (PPV)
Number of subjects: 29
Study 21185737 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Doctor plus Provider Cueing intervention
Number of subjects: 50
Study 21185737 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 18652757 — intervention group
Group type: EXPERIMENTAL
Intervention: V80/H12.5 (80 mg valsartan/12.5 mg hydrochlorothiazide)
Number of subjects: 126
Study 18652757 — intervention group
Group type: COMPARATOR
Intervention: V80 (80 mg valsartan)
Number of subjects: 126
Study 17068384 — intervention group
Group type: EXPERIMENTAL
Intervention: MALDI-TOF protein profiling
Number of subjects: 107
Study 17068384 — intervention group
Group type: COMPARATOR
Intervention: Control group (29 controls)
Number of subjects: 107
Study 12664247 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral diazepam (Dz)
Number of subjects: 0
Study 12664247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 0
Study 10560170 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 0
Study 10560170 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-counter (OTC) use of nicotine replacement therapy
Number of subjects: 0
Study 10560170 — intervention group
Group type: COMPARATOR
Intervention: Medical prescription of nicotine substitutes
Number of subjects: 0
Study 10182199 — intervention group
Group type: EXPERIMENTAL
Intervention: D.A.R.E. program participants
Number of subjects: 38
Study 10182199 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not receive D.A.R.E. program)
Number of subjects: 38
Study 2071269 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren 'A' (50 mg)
Number of subjects: 20
Study 2071269 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflaban 'B' (50 mg)
Number of subjects: 20
Study 6353620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous domperidone 10 mg
Number of subjects: 50
Study 6353620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31486721 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integrated telehealth palliative care
Number of subjects: 1250
Study 31486721 — intervention group
Group type: COMPARATOR
Intervention: In-person palliative care
Number of subjects: 1250
Study 30419404 — intervention group
Group type: EXPERIMENTAL
Intervention: Total alcoholic drinks consumption
Number of subjects: 74
Study 30419404 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consumption of total alcoholic drinks
Number of subjects: 74
Study 28278389 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived appropriateness of pulmonary nodule evaluation strategies in three clinical vignettes with different malignancy risk.
Number of subjects: 428
Study 28278389 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection as an appropriate option for pulmonary nodule management.
Number of subjects: 428
Study 28278389 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in shared decision-making with patients for pulmonary nodule management.
Number of subjects: 428
Study 28278389 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to enroll patients in randomized trials comparing nodule management strategies.
Number of subjects: 428
Study 24866259 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of health promotion, occupational health and safety, and a system for continuous improvements (Kaizen)
Number of subjects: 0
Study 23386645 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D2 daily for 11 weeks
Number of subjects: 34
Study 23386645 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3 daily for 11 weeks
Number of subjects: 34
Study 23386645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 21291957 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium valproate (MgV; 20mg/kg/day)
Number of subjects: 18
Study 21291957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19190178 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Lactobacillus plantarum bacteria
Number of subjects: 0
Study 19190178 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus plantarum bacteria
Number of subjects: 0
Study 19190178 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 17127226 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 250 mg oral, once daily (LVFX)
Number of subjects: 82
Study 17127226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg oral, twice daily (CPFX)
Number of subjects: 82
Study 17127226 — intervention group
Group type: COMPARATOR
Intervention: Placebo one tablet oral once daily (P group)
Number of subjects: 82
Study 15023707 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin 2% nasal ointment (n = 793)
Number of subjects: 1602
Study 15023707 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment (n = 809)
Number of subjects: 1602
Study 11167439 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive intra-operative suggestions
Number of subjects: 140
Study 11167439 — intervention group
Group type: COMPARATOR
Intervention: White noise (control)
Number of subjects: 140
Study 9764893 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN)
Number of subjects: 890
Study 9764893 — intervention group
Group type: COMPARATOR
Intervention: Stepwise multiple logistic regression
Number of subjects: 890
Study 8158698 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy and surgery
Number of subjects: 60
Study 8158698 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 60
Study 3336380 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 173
Study 3336380 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 173
Study 3336380 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 173
Study 29380050 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific drill template (PDT) technique
Number of subjects: 78
Study 29380050 — intervention group
Group type: COMPARATOR
Intervention: Conventional arthroscopic technique
Number of subjects: 78
Study 29380050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PDT and Arthroscopic techniques
Number of subjects: 78
Study 27163519 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.45 or 0.625 mg/Bazedoxifene (BZA) 20 mg
Number of subjects: 3424
Study 27163519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3424
Study 25697080 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted individualized falls prevention program
Number of subjects: 752
Study 25697080 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 752
Study 23324984 — intervention group
Group type: EXPERIMENTAL
Intervention: 15D health-related quality of life instrument
Number of subjects: 3268
Study 21459785 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate calcium concentration of 1.12 mmol/L
Number of subjects: 30
Study 21459785 — intervention group
Group type: COMPARATOR
Intervention: Dialysate calcium concentration of 1.37 mmol/L
Number of subjects: 30
Study 18089701 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 1200 mg/d with placebo vitamin D (Ca group)
Number of subjects: 120
Study 18089701 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 1200 mg/d with 1000 IU/d vitamin D2 (CaD group)
Number of subjects: 120
Study 18089701 — intervention group
Group type: COMPARATOR
Intervention: Double placebo (control)
Number of subjects: 120
Study 16929710 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG reactivity to eye opening
Number of subjects: 39
Study 16929710 — intervention group
Group type: EXPERIMENTAL
Intervention: Right temporal theta frequency
Number of subjects: 39
Study 16929710 — intervention group
Group type: EXPERIMENTAL
Intervention: Left central beta frequency
Number of subjects: 39
Study 16929710 — intervention group
Group type: EXPERIMENTAL
Intervention: Left parietotemporal delta frequency
Number of subjects: 39
Study 16929710 — intervention group
Group type: EXPERIMENTAL
Intervention: Right occipital alpha frequency
Number of subjects: 39
Study 12906343 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium therapy (200 microg/day)
Number of subjects: 63
Study 12906343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 10715288 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel at 175 mg/m(2) over 3 hours every 3 weeks
Number of subjects: 86
Study 10715288 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin at 130 mg/m(2) over 2 hours every 3 weeks
Number of subjects: 86
Study 8881734 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate communication of FNAB results
Number of subjects: 102
Study 8881734 — intervention group
Group type: COMPARATOR
Intervention: Delayed communication of FNAB results
Number of subjects: 102
Study 1528969 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venotonic treatment for one month
Number of subjects: 2295
Study 1528969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent venotonic treatment in parallel with active contraceptive treatment from the 10th to the 28th day
Number of subjects: 2295